Enlivex: Jumps on European patent for immunotherapy candidate

Enlivex

15/06/2021 14:14

** U.S.-listed shares of Israel-based drug developer Enlivex
Therapeutics  ENLV.O  rise ~2% to $9.95 premarket
    ** European Patent Office issues new patent for co's
experimental therapy, Allocetra, which is being developed to
treat diseases such as solid cancers, sepsis and COVID-19 
 urn:newsml:reuters.com:*:nGNX9zgjhg
    ** Patent further strengthens existing IP portfolio covering
the use of Allocetra for cancer therapy - ENLV
    ** ENLV is currently testing Allocetra in severe and
critical COVID-19 patients as well as patients with organ
failure associated with sepsis
    ** Shares jumped as much as 30% on Feb 3 after co said 14 of
16 COVID-19 patients treated with Allocetra in a mid-stage trial
recovered completely and were discharged from hospital
 urn:newsml:reuters.com:*:nL4N2K93RB
    ** U.S.-listed ENLV shares up about 16% this year, as of
last close 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))